To assess the effects of antigenic reporters on response to molecularly-targeted therapeutic agents, we employed the melanoma GDA model HCmel12 (derived from an HGF/CDK4R24C-transgenic mouse [18]), labeled ex vivo with ffLuc-eGFP, and transplanted subcutaneously into syngeneic GH or WT c-Brd mice. The gene discussed is HGF; the disease is melanoma.